CL2A

• Description:

  CL2A is a claevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. Labetuzumab govitecan used this linker[1].

• UNSPSC:

  12352203

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  ADC Linker

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/cl2a.html

• Purity:

  98.20

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(NC1=CC=C(CO)C=C1)[C@H](CCCCN)NC(COCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCN2N=NC(CNC(C3CCC(CN4C(C=CC4=O)=O)CC3)=O)=C2)=O)=O

• Molecular Formula:

  C50H79N9O16

• Molecular Weight:

  1062.21

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Samantha Congreve, et al. Antibody drug conjugates (ADC) . Teknisk- naturvetenskaplig fakultet

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, protect from light)

• Scientific Category:

  ADC Related

• Clinical Information:

  Phase 2

• Isoform:

  Cleavable Linker

• CAS Number:

  [2616704-22-2]